APL-1202
Product Pipeline
Therapeutic Areas
R&D Strategy
Product Pipeline
Asieris Pharmaceuticals focuses on the development of new anti-cancer and anti-multi-drug resistance infection drugs with high market potentials, and we do so through internal research and collaboration with the world's leading research institutions. Meanwhile, we leverage our leading position in the field of urological cancers to selectively in-license products from foreign companies for joint development of the China market.
product pipeline

Our product pipeline is as follows. We are initiating APL-1202's domestic Pivotal Trial , the second-generation product APL-1301's international Phase II trial, as well as advancing other new drug projects.

APL-1202

APL-1301

APL-1401

APL-1501